Aurigene Declares phase 1 study for novel autologous CAR-T cell therapy

Aurigene Oncology Limited, a subsidiary of Dr Reddy’s Laboratories Limited, is dedicated to developing innovative treatments for cancer and has released phase 1 findings for DRL-1801 in the SWASTH study - India's initial trial for a new CAR-T cell therapy for multiple myeloma patients.

The research presented early findings from the initial 8 participants. Every patient had a significant history of prior treatment, averaging 5.5 previous lines. The majority of patients had undergone a previous transplant and experienced disease advancement after the transplant. Every one of the 8 patients showed clinical improvement, and 5 out of 8 (62.5%) achieved stringent complete remission. Regarding safety, there were no severe instances of cytokine release syndrome (CRS) or neurotoxicity observed in any of the patients.

Following the analysis of phase 1 results, the Drugs Controller General of India (DCGI) has approved the initiation of phase 2 clinical trial. The findings from stage 1 were demonstrated during the 21st annual gathering of the International Myeloma Society in Rio De Janeiro, Brazil, which took place not long ago.

“The results from the trial in heavily pre-treated relapsed refractory myeloma patients are very exciting for us in India. We are thrilled with the data, as the drug could be transformative for Indian patients with myeloma” commented Dr. Murali Ramachandra, CEO, Aurigene Oncology.